CJC-1295

Description

CJC-1295 Reference Material | Albumin-Binding GHRH Analog

CJC-1295 with DAC is a modified GHRH analog incorporating a maleimido-propionamide (MPA) group that covalently binds serum albumin, extending its effective half-life to approximately 6–8 days in preclinical models. This albumin-binding technology transforms the short-acting GHRH sequence into a sustained-release GHRH receptor ligand suited for chronic somatotroph stimulation research.

Research Applications

• GHRH receptor agonism and sustained cAMP signaling in pituitary somatotrophs
• Long-term GH/IGF-1 axis modulation in preclinical animal models
• Albumin-binding peptide pharmacokinetics and depot-release research
• GH pulsatility studies under sustained GHRH receptor occupancy
• Combination somatotroph stimulation paradigms with GHSR-1a agonists

CJC-1295 with DAC vs. without DAC

Researchers select CJC-1295 with DAC for studies requiring sustained baseline GH/IGF-1 elevation. CJC-1295 without DAC (Mod GRF 1-29) is preferred for studies requiring preserved GH pulsatility patterns without continuous receptor occupancy.

Specifications

• Molecular Weight: 3,647.3 g/mol
• Form: Lyophilized powder
• Purity: ≥98% (HPLC verified)
• Storage: 2–8°C; -20°C long-term

For laboratory research use only. Not for human or veterinary use.